Reframing the Trimethylamine–Trimethylamine N-Oxide Axis in Chronic Kidney Disease: A Life-Course Perspective

Elevated circulating trimethylamine N-oxide (TMAO) is a well-established biomarker of cardiorenal risk; however, accumulating evidence reveals a “causality paradox” that supports a paradigm shift toward the integrated trimethylamine (TMA)–TMAO axis. Rather than acting solely as a downstream metabolite, TMAO serves as a context-dependent indicator of diet–gut microbiota–liver–kidney interactions, whereas gut microbiota-derived TMA functions as a proximal bioactive mediator of vascular toxicity, at least in part through TAAR5 activation, thereby contributing to the initiation of cardiorenal injury. This revised framework helps resolve the “fish paradox” and distinguishes systemic biomarker concentrations from localized, tissue-specific pathogenic processes. This narrative review examines the TMA–TMAO axis through a life-course and Developmental Origins of Health and Disease (DOHaD) perspective, highlighting how maternal chronic kidney disease (CKD) and altered prenatal metabolite exposure can program hypertension and kidney disease in offspring. We further discuss the limitations of relying on static plasma TMAO concentrations, which reflect the combined influences of dietary intake, hepatic flavin monooxygenase activity, gut microbial metabolism, and impaired renal clearance. To overcome these limitations, we advocate dynamic, flux-based metabolic assessment using integrated measurements and ratios of TMA, TMAO, and dimethylamine (DMA). Finally, we propose a four-stage cyclic precision medicine framework that emphasizes early identification of high-risk individuals during critical developmental windows, longitudinal monitoring of systemic toxic burden using rapid and cost-effective point-of-care nanozyme assays, measurement of metabolic flux rather than static metabolite concentrations, and personalized intervention through multimodal strategies, including dietary and prebiotic modulation, non-lethal microbial choline TMA-lyase inhibitors, and computational digital twins for predictive risk stratification. Collectively, shifting the focus from isolated metabolites to the integrated TMA–TMAO axis provides a mechanistically informed, life-course strategy for precision prevention and potential intergenerational influences on cardiorenal health.

Authors

Institutions

Publication Details

Journal
Nutrients
Published
2026-11-18
DOI
https://doi.org/10.3390/nu18223840
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Reframing the Trimethylamine–Trimethylamine N-Oxide Axis in Chronic Kidney Disease: A Life-Course Perspective

You‐Lin Tain, Chien‐Ning Hsu
1 links
Nutrients
Gut microbiota and health
article

Reframing the Trimethylamine–Trimethylamine N-Oxide Axis in Chronic Kidney Disease: A Life-Course Perspective

You‐Lin Tain, Chien‐Ning Hsu
article en

Abstract

Elevated circulating trimethylamine N-oxide (TMAO) is a well-established biomarker of cardiorenal risk; however, accumulating evidence reveals a “causality paradox” that supports a paradigm shift toward the integrated trimethylamine (TMA)–TMAO axis. Rather than acting solely as a downstream metabolite, TMAO serves as a context-dependent indicator of diet–gut microbiota–liver–kidney interactions, whereas gut microbiota-derived TMA functions as a proximal bioactive mediator of vascular toxicity, at least in part through TAAR5 activation, thereby contributing to the initiation of cardiorenal injury. This revised framework helps resolve the “fish paradox” and distinguishes systemic biomarker concentrations from localized, tissue-specific pathogenic processes. This narrative review examines the TMA–TMAO axis through a life-course and Developmental Origins of Health and Disease (DOHaD) perspective, highlighting how maternal chronic kidney disease (CKD) and altered prenatal metabolite exposure can program hypertension and kidney disease in offspring. We further discuss the limitations of relying on static plasma TMAO concentrations, which reflect the combined influences of dietary intake, hepatic flavin monooxygenase activity, gut microbial metabolism, and impaired renal clearance. To overcome these limitations, we advocate dynamic, flux-based metabolic assessment using integrated measurements and ratios of TMA, TMAO, and dimethylamine (DMA). Finally, we propose a four-stage cyclic precision medicine framework that emphasizes early identification of high-risk individuals during critical developmental windows, longitudinal monitoring of systemic toxic burden using rapid and cost-effective point-of-care nanozyme assays, measurement of metabolic flux rather than static metabolite concentrations, and personalized intervention through multimodal strategies, including dietary and prebiotic modulation, non-lethal microbial choline TMA-lyase inhibitors, and computational digital twins for predictive risk stratification. Collectively, shifting the focus from isolated metabolites to the integrated TMA–TMAO axis provides a mechanistically informed, life-course strategy for precision prevention and potential intergenerational influences on cardiorenal health.

NutrientsVol. 18(22)
National Sun Yat-sen University (TW), Kaohsiung Medical University (TW), Chang Gung University (TW), Kaohsiung Chang Gung Memorial Hospital (TW)
Kaohsiung Chang Gung Memorial Hospital
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon